The 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT2026) began July 9 at the Gaylord Pacific Resort & Convention Center in Chula Vista, California, welcoming attendees and journalists with a range of scientific sessions, workshops, and technology showcases.
A press room is available for journalists in California Office 3 on Level 1, outside the Exhibit Hall, with staffed hours from July 10 to July 12. Jess Frizen, Senior Manager of Content and Member Communications at SCCT, is the primary contact for media inquiries. The meeting will feature the announcement of the Best Original Science award on July 11 and the introduction of the 2026-27 SCCT leadership team on July 12. SCCT also announced that its next global meeting will be held in Ireland in 2027.
Elucid, a Boston-based AI medical technology company, announced its largest presence to date at SCCT2026, presenting a broad portfolio of scientific, educational, and exhibition activities. According to Elucid, the company will highlight its vision for the next era of cardiovascular imaging, centered on the theme 'From Lesion-Level Risk to Patient-Level Impact.' The program will demonstrate advances in histology-validated plaque analysis and plaque-derived physiology, with a focus on personalized cardiovascular care. Elucid's plaque-derived FFR-CT is currently under review by the U.S. Food and Drug Administration. The company will participate in multiple sessions, including an AI & Innovations Symposium, interactive workshops, product showcases, and a sponsored lunch symposium.
The SCCT recently released an expert consensus document in collaboration with the Society for Cardiovascular Angiography and Interventions, providing guidelines for the use of coronary CT angiography-derived fractional flow reserve (FFR-CT) in assessing coronary artery disease. The document, published in the Journal of Cardiovascular Computed Tomography and endorsed by the American College of Cardiology, emphasizes the role of FFR-CT in improving diagnostic accuracy and guiding clinical management, according to the Society of Cardiovascular Computed Tomography.
Several awards will be presented during the meeting. Michael Shapiro, DO, will receive the 2026 Arthur S. Agatston Cardiovascular Disease Prevention Award for his contributions to preventive cardiology. Jonathon Leipsic, MD, will be honored with the 2026 Stephan Achenbach Pioneer Award for his work in advancing cardiac CT, and Edward Nicol, MD, will receive the 2026 Gold Medal Award for Distinguished Service. The SCCT also named Ido Avivi, MD, as the recipient of the Chinnaiyan Catalyst Award for Women's Cardiovascular Health Research for his project on coronary plaque characterization in postmenopausal women on hormone replacement therapy, according to the Society of Cardiovascular Computed Tomography.
The exhibit hall will showcase advances in cardiovascular imaging technology, with SCCT President Kavitha Chinnaiyan, MD, describing the field's progression from detection and diagnosis to patient management and treatment. "Advances in scanner technology, computational analysis and imaging analytics now allow clinicians to examine atherosclerosis with far greater depth. Plaque burden can be quantified, plaque composition characterized and patterns of vascular remodeling detected and followed over time. These capabilities are transforming CT from a purely anatomical tool into a platform for understanding the biology of coronary disease," Chinnaiyan wrote in the Journal of Cardiovascular Computed Tomography, according to the Society of Cardiovascular Computed Tomography.
